vs
Amphastar Pharmaceuticals, Inc.（AMPH）とXometry, Inc.（XMTR）の財務データ比較。上の社名をクリックして会社を切り替えられます
Xometry, Inc.の直近四半期売上が大きい（$192.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.1倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -4.5%、差は17.8%）。Xometry, Inc.の前年同期比売上増加率が高い（29.5% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-5.9M）。過去8四半期でXometry, Inc.の売上複合成長率が高い（25.2% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Xometryはオンデマンドで製造部品を調達するためのオンラインマーケットプレイスで、試作から大量生産までのニーズに対応しています。業種を問わず顧客の調達プロセスを効率化し、製品開発のリードタイム短縮を支援しています。
AMPH vs XMTR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $192.4M |
| 純利益 | $24.4M | $-8.6M |
| 粗利率 | 46.8% | 39.1% |
| 営業利益率 | 19.4% | -4.6% |
| 純利益率 | 13.3% | -4.5% |
| 売上前年比 | -1.8% | 29.5% |
| 純利益前年比 | -35.7% | 12.7% |
| EPS（希薄化後） | $0.51 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $192.4M | ||
| Q3 25 | $191.8M | $180.7M | ||
| Q2 25 | $174.4M | $162.5M | ||
| Q1 25 | $170.5M | $151.0M | ||
| Q4 24 | $186.5M | $148.5M | ||
| Q3 24 | $191.2M | $141.7M | ||
| Q2 24 | $182.4M | $132.6M | ||
| Q1 24 | $171.8M | $122.7M |
| Q4 25 | $24.4M | $-8.6M | ||
| Q3 25 | $17.4M | $-11.6M | ||
| Q2 25 | $31.0M | $-26.4M | ||
| Q1 25 | $25.3M | $-15.1M | ||
| Q4 24 | $38.0M | $-9.9M | ||
| Q3 24 | $40.4M | $-10.2M | ||
| Q2 24 | $37.9M | $-13.7M | ||
| Q1 24 | $43.2M | $-16.6M |
| Q4 25 | 46.8% | 39.1% | ||
| Q3 25 | 51.4% | 39.9% | ||
| Q2 25 | 49.6% | 40.1% | ||
| Q1 25 | 50.0% | 37.3% | ||
| Q4 24 | 46.5% | 39.7% | ||
| Q3 24 | 53.3% | 39.4% | ||
| Q2 24 | 52.2% | 39.9% | ||
| Q1 24 | 52.4% | 39.0% |
| Q4 25 | 19.4% | -4.6% | ||
| Q3 25 | 13.2% | -6.1% | ||
| Q2 25 | 24.2% | -6.3% | ||
| Q1 25 | 21.9% | -10.2% | ||
| Q4 24 | 24.2% | -7.8% | ||
| Q3 24 | 29.8% | -8.1% | ||
| Q2 24 | 30.3% | -11.5% | ||
| Q1 24 | 27.9% | -14.6% |
| Q4 25 | 13.3% | -4.5% | ||
| Q3 25 | 9.0% | -6.4% | ||
| Q2 25 | 17.8% | -16.3% | ||
| Q1 25 | 14.8% | -10.0% | ||
| Q4 24 | 20.4% | -6.7% | ||
| Q3 24 | 21.1% | -7.2% | ||
| Q2 24 | 20.8% | -10.3% | ||
| Q1 24 | 25.1% | -13.5% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $219.1M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $275.6M |
| 総資産 | $1.6B | $703.7M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $219.1M | ||
| Q3 25 | $276.2M | $224.5M | ||
| Q2 25 | $231.8M | $225.8M | ||
| Q1 25 | $236.9M | $231.4M | ||
| Q4 24 | $221.6M | $239.8M | ||
| Q3 24 | $250.5M | $234.0M | ||
| Q2 24 | $217.8M | $240.9M | ||
| Q1 24 | $289.6M | $253.8M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $275.6M | ||
| Q3 25 | $776.7M | $272.0M | ||
| Q2 25 | $757.5M | $270.4M | ||
| Q1 25 | $751.3M | $309.9M | ||
| Q4 24 | $732.3M | $314.5M | ||
| Q3 24 | $727.7M | $315.2M | ||
| Q2 24 | $713.3M | $315.8M | ||
| Q1 24 | $672.4M | $320.4M |
| Q4 25 | $1.6B | $703.7M | ||
| Q3 25 | $1.7B | $698.9M | ||
| Q2 25 | $1.6B | $687.0M | ||
| Q1 25 | $1.6B | $690.1M | ||
| Q4 24 | $1.6B | $680.1M | ||
| Q3 24 | $1.5B | $678.2M | ||
| Q2 24 | $1.5B | $678.6M | ||
| Q1 24 | $1.6B | $692.5M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $4.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-5.9M |
| FCFマージンFCF / 売上 | 13.4% | -3.0% |
| 設備投資強度設備投資 / 売上 | 4.5% | 5.3% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-24.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $4.4M | ||
| Q3 25 | $52.6M | $5.8M | ||
| Q2 25 | $35.6M | $-427.0K | ||
| Q1 25 | $35.1M | $-3.7M | ||
| Q4 24 | $29.0M | $9.1M | ||
| Q3 24 | $60.0M | $-3.6M | ||
| Q2 24 | $69.1M | $-9.1M | ||
| Q1 24 | $55.3M | $-11.7M |
| Q4 25 | $24.6M | $-5.9M | ||
| Q3 25 | $47.2M | $-1.7M | ||
| Q2 25 | $25.0M | $-7.4M | ||
| Q1 25 | $24.4M | $-9.2M | ||
| Q4 24 | $16.6M | $4.5M | ||
| Q3 24 | $46.2M | $-8.4M | ||
| Q2 24 | $63.1M | $-13.5M | ||
| Q1 24 | $46.5M | $-16.1M |
| Q4 25 | 13.4% | -3.0% | ||
| Q3 25 | 24.6% | -0.9% | ||
| Q2 25 | 14.3% | -4.5% | ||
| Q1 25 | 14.3% | -6.1% | ||
| Q4 24 | 8.9% | 3.1% | ||
| Q3 24 | 24.1% | -6.0% | ||
| Q2 24 | 34.6% | -10.2% | ||
| Q1 24 | 27.1% | -13.1% |
| Q4 25 | 4.5% | 5.3% | ||
| Q3 25 | 2.8% | 4.1% | ||
| Q2 25 | 6.1% | 4.3% | ||
| Q1 25 | 6.3% | 3.6% | ||
| Q4 24 | 6.7% | 3.1% | ||
| Q3 24 | 7.2% | 3.4% | ||
| Q2 24 | 3.3% | 3.3% | ||
| Q1 24 | 5.1% | 3.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
